RecruitingPhase 1NCT07114939

FTT PET/CT in Pancreatic Neuroendocrine Tumors

PARP-1 Targeting With the Novel Radiotracer [18F]FTT in Pancreatic Neuroendocrine Tumors

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

12 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

Pancreatic Tumors Neuroendocrine Carcinoma Metastatic

Summary

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial uses a new type of PET/CT scan with an experimental imaging tracer to better detect and map pancreatic neuroendocrine tumors (a type of pancreatic cancer). The goal is to see whether this imaging can more accurately show where the cancer is and guide treatment decisions. **You may be eligible if...** - You are 18 or older - You have been diagnosed with metastatic or inoperable pancreatic neuroendocrine tumor (grade 1, 2, or 3) - You have at least one tumor that is 1.5 cm or larger on imaging - You may be receiving treatment already or not — both are welcome **You may NOT be eligible if...** - All your liver disease has been treated and you have not yet shown progression again - You are pregnant or breastfeeding - You have a medical condition that would make it unsafe to complete the scan - You are unable to tolerate the imaging procedure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]FluorThanatrace

Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.

Locations(1)

University of Pennsylvania, Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07114939

Related Trials

An International Study on Pediatric Patients With Rare Tumors.

NCT070721431 location